에서 실시간으로 운영 중이에요! 자세히 알아보기

ProPhase Labs

PRPH

시가총액 US$152만

상장 폐지됨

PRPH 종목은 2026년 1월 2일에 상장 폐지됐어요.

순위로 돌아가기

소개: ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.

직원 수: 96

헬스케어 진단 및 리서치

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value

UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's underlying asset base.

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript

ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript

ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript

Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1

UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Lab's Chairman and CEO Ted Karkus.

Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1

ProPhase Labs, Inc. (PRPH) Q3 2025 Earnings Call Transcript

ProPhase Labs, Inc. ( PRPH ) Q3 2025 Earnings Call November 19, 2025 2:00 PM EST Company Participants Ted Karkus - Chairman & CEO Presentation Operator Hello, and good afternoon, everyone. Welcome to today's presentation.

ProPhase Labs, Inc. (PRPH) Q3 2025 Earnings Call Transcript

ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important.

ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting third quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on November 19, 2025, at 2:00 pm EST. A press release detailing these results will be issued prior to the virtual conference call.

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals

UNIONDALE, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) reminds shareholders of record as of October 20, 2025, of the Company's upcoming Special Meeting of Stockholders, which will be held on November 24, 2025, at 10:00 a.m. ET. Shareholders of record as of October 20, 2025, will be able to attend the Special Meeting in person at 273 Merrick Road, Lynbrook, NY 11563.

ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals

ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology

Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer Progression

ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts

UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts. “We are entering a transformative phase for ProPhase,” said Ted Karkus, CEO and Chairman of ProPhase Labs.

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.